Johnson&Johnson sales bolstered again by devices and diagnostics as Cypher and new hips and knees forge ahead
This article was originally published in Clinica
Executive Summary
Continuing the trend of the past several quarters, Johnson & Johnson's medical device and diagnostics businesses helped prop up sales growth as US pharmaceutical revenues suffered from increasing generic drug competition.